Bristol Myers Squibb (BMY) stock news

Bristol Myers Squibb (BMY) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-09-25 14:00:00 UTC#369180newconfirmednews

Bristol Myers Squibb's ZENBEXUS combo hits 41.1% MRD-negative CR in Phase 3 EXCALIBER-RRMM trial

tradingviewimportance 0.60trust 0.70Bristol Myers Squibb Company +0.60ZENBEXUS +0.60daratumumab +0.20+2 entities

2026-09-24 08:50:00 UTC#361040newconfirmednews

Zacks adds Bristol-Myers Squibb (BMY), Heritage Insurance (HRTG), and Red Violet (RDVT) to Strong Buy list

yahooimportance 0.30trust 0.60Bristol-Myers Squibb Company +0.40Heritage Insurance Holdings, Inc. +0.40Red Violet, Inc. +0.40+1 entities

2026-09-21 11:28:15 UTC#342048duplicateconfirmednews

Bristol-Myers Squibb weekly recap: Amgen Opdivo patent suit, $15.2B Hengrui deal, and $0.63 dividend

tradingviewimportance 0.30trust 0.70Bristol-Myers Squibb Company +0.30Amgen Inc. -0.40Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.50+2 entities

2026-09-21 11:16:29 UTC#341825newconfirmednews

Sichuan Biokin Pharmaceutical receives $250 million milestone payment from Bristol-Myers Squibb for IZA-BREN

reutersimportance 0.50trust 0.90Sichuan Biokin Pharmaceutical Co., Ltd. +0.60Bristol-Myers Squibb Company +0.30iza-bren +0.40

2026-09-17 10:59:00 UTC#326797newconfirmednews

Bristol Myers Squibb reports 2-year Sotyktu efficacy and safety data from POETYK PsA-2 study

tradingviewimportance 0.40trust 0.70Bristol Myers Squibb Company +0.40Sotyktu +0.50POETYK PsA-2 +0.40

2026-09-16 17:24:46 UTC#322372newconfirmednews

Piper Sandler reiterates Overweight rating on Bristol-Myers Squibb, maintains $82 price target

tradingview_analyst_updatesimportance 0.30trust 0.70Piper Sandler Companies +0.20Bristol-Myers Squibb Company +0.30

2026-09-16 14:31:00 UTC#321453newconfirmednews

DelveInsight Report Projects Sjögren's Syndrome Market Growth Through 2036 Driven by New Targeted Therapies

yahooimportance 0.30trust 0.50DelveInsight 0Amgen Inc. +0.30Johnson & Johnson +0.30+2 entities

2026-09-16 11:16:03 UTC#320171newconfirmednews

Bristol-Myers Squibb Company declares quarterly dividend of $0.63 per share

seeking alphaimportance 0.30trust 0.80Bristol-Myers Squibb Company +0.20

2026-09-15 17:37:14 UTC#315922duplicateconfirmednews

Bristol Myers sues Amgen to block U.S. biosimilar of cancer drug Opdivo

reuters.comimportance 0.40trust 0.90Bristol-Myers Squibb Company +0.20Amgen Inc. -0.30Opdivo +0.10

2026-09-15 17:28:45 UTC#315859newconfirmednews

Bristol Myers and Ono sue Amgen to block U.S. biosimilar of cancer drug Opdivo

reutersimportance 0.60trust 0.90Bristol Myers Squibb Co. -0.20Amgen Inc. -0.30Ono Pharmaceutical Co., Ltd. -0.20+2 entities

2026-09-14 13:05:00 UTC#307503newconfirmedpress release

BioMarin Pharmaceutical appoints Bristol Myers Squibb Chief Research Officer Robert Plenge to Board of Directors

pr newswireimportance 0.30trust 1.00BioMarin Pharmaceutical Inc. +0.20Robert Plenge +0.20Bristol Myers Squibb 0

2026-09-10 14:08:00 UTC#292791newconfirmednews

HSBC maintains Hold rating on Bristol-Myers Squibb (BMY)

dow_jonesimportance 0.30trust 0.70Bristol-Myers Squibb Company 0HSBC Holdings plc 0

2026-09-08 11:28:46 UTC#280245duplicateconfirmednews

Bristol Myers Squibb reports positive Phase 2 QUINTESSENTIAL trial results for Arlocabtagene autoleucel

reutersimportance 0.40trust 0.90Bristol-Myers Squibb Company +0.50QUINTESSENTIAL +0.50

2026-09-08 11:20:37 UTC#280163duplicateconfirmednews

Bristol Myers Squibb reports positive mid-stage trial results for CAR-T cell therapy in multiple myeloma

seeking alphaimportance 0.30trust 0.70Bristol Myers Squibb Company +0.50Arlocabtagene autoleucel +0.50

2026-09-08 11:16:36 UTC#280137duplicateconfirmednews

Bristol Myers Squibb blood cancer cell therapy meets primary endpoint in mid-stage trial

reutersimportance 0.30trust 0.90Bristol Myers Squibb Company +0.50

2026-09-08 11:12:31 UTC#280089duplicateconfirmednews

Bristol Myers Squibb's arlo-cel meets primary and secondary endpoints in mid-stage multiple myeloma trial

reutersimportance 0.30trust 0.90Bristol Myers Squibb Company +0.50arlocabtagene autoleucel +0.50

2026-09-08 11:03:06 UTC#280043newconfirmednews

Bristol Myers Squibb experimental cell therapy meets primary endpoint in mid-stage trial

reutersimportance 0.40trust 0.90Bristol Myers Squibb Company +0.50

2026-09-08 10:59:00 UTC#280083duplicateconfirmedpress release

Bristol Myers Squibb reports positive Phase 2 QUINTESSENTIAL trial results for Arlocabtagene autoleucel

yahooimportance 0.60trust 1.00Bristol Myers Squibb Company +0.60Arlocabtagene autoleucel +0.60QUINTESSENTIAL +0.60+2 entities

2026-09-04 10:39:00 UTC#267703duplicateconfirmednews

WSJ Daily Briefing: Novartis and Bristol Myers halt autoimmune trials; Fetterman scrutiny continues

dow_jonesimportance 0.40trust 0.90John Fetterman -0.40Novartis AG -0.50Bristol Myers Squibb Company -0.50+2 entities

2026-09-03 22:00:00 UTC#265384duplicateconfirmednews

Novartis and Bristol Myers Halt Autoimmune Trials Following Patient Deaths and Severe Side Effects

wsjimportance 0.60trust 0.90Novartis AG -0.70Bristol-Myers Squibb Company -0.70